BioSpace News Archive

MacroGenics, Inc. announced that the Company’s management will participate in the following investor conferences in September 2022.

Jacobio Pharma (1167.HK) announced it has completed first patient dosage of it’s in-house R&D drug candidate CD73 monoclonal antibody JAB-BX102 in a Phase I/IIa clinical trial for advanced solid tumour patients.

Developer of an ultrasensitive protein detection platform, Spear Bio (www.spear.bio), presented its breakthrough immunoassay technology at the recent American Association of Clinical Chemistry’s scientific meeting and clinical lab expo, held in Chicago.

Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose-forms and formulations of products to serve the needs of overlooked patients, announced today that the U.S. Food and Drug Administration (FDA) has approved Konvomep™ (omeprazole and sodium bicarbonate for oral suspension).

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 18,000 shares of KalVista common stock on September 1, 2022 as inducements material to each employee entering into employment with KalVista.

Precision BioSciences, Inc. announced promotions and organizational changes that impact responsibilities within the company’s senior leadership team reporting to Michael Amoroso, Chief Executive Officer.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Neha Krishnamohan has been appointed to the Arcutis Board of Directors and as a member of the audit committee.

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its Fiscal Year ended June 30, 2022.

Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences.

InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV) will release its 2022 fiscal fourth quarter financial results on Tuesday, September 13, 2022, after market close.